According to the Interface News APP, glaxosmithkline (GSK.US) stated on Tuesday that its respiratory syncytial virus (RSV) vaccine has protective effects in the three quarters after vaccination. Data adjusted for seasonal factors show that the cumulative effectiveness of this vaccine for the elderly over three quarters is 62.9%.

These data are crucial for vaccine advisory groups, doctors, and patients to decide which RSV vaccine to administer. GlaxoSmithKline faces fierce competition from pfizer (PFE.US) and moderna (MRNA.US).

The vaccine has been approved for use in all adults aged 60 and over in the USA and the EU, as well as high-risk individuals aged 50 to 59.

GlaxoSmithKline is the first vaccine manufacturer to submit efficacy data for RSV vaccine over three quarters. In the northern hemisphere, the RSV epidemic season lasts from October to March of the following year, affecting tens of millions of people annually. In terms of disease and mortality, RSV has the greatest impact on infants and the elderly.

GlaxoSmithKline's data shows that vaccine efficacy gradually decreases, from 56.1% in the second quarter to 48% in the third quarter. Due to different definitions of severe RSV disease, it is difficult to directly compare the efficacy of various vaccines. Nevertheless, Moderna's vaccine efficacy is believed to decline faster than its competitors.

GlaxoSmithKline's new data does not directly indicate when a vaccine may need to be re-administered. The company's Chief Scientific Officer Tony Wood stated that the company will continue to provide long-term follow-up data to aid in determining future re-vaccination plans.